Skip to main content

Inhibikase Therapeutics, Inc 8-K, filed Nov 10, 2026

Inhibikase Therapeutics, Inc. (IKT)

8-K 2026-11-10 For: 2026-11-10
View Original
Added on November 10, 2026

About this 8-K

Inhibikase Therapeutics, Inc filed this 8-K on November 10, 2026.

Inhibikase Therapeutics reported 28 country regulatory approvals and 79 activated clinical sites for IMPROVE-PAH. Cash, cash equivalents and marketable securities totaled $193.3 million, while quarter-ended net loss was $20.5 million, or $0.10 per share. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits